blank_1920_347


Alanine Transferase (ALT)

Alanine Transferase (ALT) is an enzyme which is predominantly hepatic in origin. Whilst changes in serum level can often occur with AST, ALT is much more specific for liver and indicates possible hepatocyte injury. Alanine Transferase (ALT) is usually one of a group of tests used to investigate the health of the liver.

One of the most common causes of very elevated ALT levels is due to acute hepatitis, most commonly viral hepatitis. It often increases before and peaks near the onset of jaundice in viral hepatitis.  Levels can remain raised for 1 – 2 months but can take longer to return to baseline, up to 3 – 6 months.

Clinical Details

ALT concentrations can fluctuate with chronic hepatitis, not all patients will have a raised level.  Moderately elevated levels can occur with high alcohol consumption, in diabetic patients, with hyperlipidaemia all of which can cause fatty liver disease. Patients with cirrhosis, non-alcoholic steatohepatitis, cholestatic liver disease, fatty liver and hepatic tumours typically have a slightly raised ALT. Other causes include haemochromatosis, autoimmune hepatitis, primary biliary cirrhosis and thyroid disorders.

Analysing the relationship between AST and ALT, (AST: ALT ratio) is often useful; it can be suggestive of certain conditions as there is considerable overlap. However, it is not exclusive and only serves as an aid to clinical decision-making.  If the AST:ALT ratio is greater than two, it is more suggestive of alcoholic liver disease. In contrast, viral hepatitis causes ALT to rise more than AST, and the ratio is usually <1, particularly true of hepatitis C.  In Wilson’s disease can cause the AST/ALT ratio to exceed 4.

Transaminases 2-5 times the upper limit of normal are often seen in chronic viral hepatitis and non-alcohol steatohepatitis (NASH). Transaminases are rarely > 10 times the upper limit of normal in uncomplicated alcoholic hepatitis. Transaminases > 20 times can indicate acute viral infection, ischaemic hepatitis, drug or paracetamol toxicity.

Case Study
At Enfer Medical, we have integrated a cutting-edge and fully automated WASPLab® (Walk Away Specimen Processor) that has significantly enhanced our testing capabilities to ensure the highest of quality when processing patient samples.
blank_532_358
blank_532_358
WASPLab® at Enfer Medical
Our entire microbiology workflow has been optimized using automation and highly sophisticated robots to ensure uninterrupted incubation for rapid bacterial growth and improved turnaround times for patients.
blank_532_358

Our Services

Service
Health & Wellness
General health and wellness testing can include a variety of tests, depending on the needs of the individual or recommendations of
Find Out More
Service
Sexual Health
Regular STI screening facilitates early treatment and reduces the long-term consequences of infection.
Find Out More
Service
Respiratory Health
Rapid early pathogen identification has important treatment and infection control implications. See our range of tests here.
Find Out More
Service
Reproductive & Female Health
Hormonal analysis is hugely beneficial to identifying problems that can arise during the reproductive years.
Find Out More
Service
All Services
View the full suite of services at Enfer Medical here.......
Find Out More
Sample Type &
Volume Required

5mL venous serum or plasma

blank_711_422
blank_336_232
blank_711_422
blank_336_232
blank_727_647
blank_711_422
blank_336_232
blank_711_422
blank_336_232
Transporting
Samples

In addition to the packaging of samples, the transport/delivery of clinical samples to the laboratory is required to be in adherence to all national regulations for the safe transport of biological materials. Enfer Medical provides a fully compliant logistics service, aligned with clients’ testing requirements.

Prompt transport of specimens:
To ensure prompt testing of samples and release of results within the published test turnaround times, samples should arrive to the laboratory by 18:00. Test turnaround time is measured from receipt of the sample at the laboratory until the time the authorised results are reported to users.

Acceptance/Rejection
of Samples

In rare cases specimens may not be suitable for testing on arrival to the laboratory. In that case the sample will be rejected at the receipt stage and the service user will be notified immediately and an explanation as to why the sample could not be processed will be provided. Reasons why samples cannot be processed include but are not limited to:

  • Samples received beyond the stability limits and/or not at the correct temperature indicated for each test.
  • Incorrect sample type received.
  • Leaking samples, sample not received or sample insufficient for analysis as stated below within sample requirements.
  • Non-compliant samples or request forms i.e. those missing sample date information, missing sample test request and/or missing sample site/type information.
  • Samples received without the necessary patient identifiers.
Clients will be provided with guidance on Sample Receipt Anomalies.

Our Services

Service
Health & Wellness
General health and wellness testing can include a variety of tests, depending on the needs of the individual or recommendations of
Find Out More
Service
Sexual Health
Regular STI screening facilitates early treatment and reduces the long-term consequences of infection.
Find Out More
Service
Respiratory Health
Rapid early pathogen identification has important treatment and infection control implications. See our range of tests here.
Find Out More
Service
Reproductive & Female Health
Hormonal analysis is hugely beneficial to identifying problems that can arise during the reproductive years.
Find Out More
Service
All Services
View the full suite of services at Enfer Medical here.......
Find Out More
Result Values:

Quantitative results for Alanine Transferase (ALT) are reported in numeric value in U/L.  Please contact us for more information on the reference ranges used at Enfer Medical.

Critical results are communicated in accordance with the Communication of critical results for patients in the community- national laboratory handbook CSP041/2019

 

blank_711_422
blank_336_232